SCHEMBL6366299

SCHEMBL6366299

CN1CC(=O)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.58
CES1 P23141 5/20 0.45
TTR P02766 1/20 0.45
BCHE P06276 2/20 0.44
KCNN4 O15554 3/20 0.41
KCNA3 P22001 3/20 0.41
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH2 P05091 1/20 0.40
ALDH3A1 P30838 1/20 0.40
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
CDC25A P30304 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30776885 1.00 NOTUM (0.58) NOTUMCES1TTRBCHEKCNN4
SCHEMBL69754 0.79 NOTUM (0.46) NOTUMCES1TTRBCHEKMT2A
SCHEMBL26487743 0.78 CASP3 (0.47) NOTUMCES1TTRBCHEKCNN4
SCHEMBL14408830 0.76 MEN1 (0.50) NOTUMCES1TTRBCHEKMT2A
SCHEMBL29960722 0.76 MEN1 (0.50) NOTUMCES1TTRBCHEKMT2A
SCHEMBL86299 0.76 MAOA (0.50) CES1TTRBCHEKMT2AALDH1A1
SCHEMBL7421554 0.75 CES1 (0.47) NOTUMCES1TTRBCHEALDH1A1
SCHEMBL9025184 0.75 CASP3 (0.46) NOTUMCES1TTRBCHEKMT2A
SCHEMBL3800178 0.74 KMT2A (0.42) KMT2AALDH1A1MAPTKDM4ELMNA
SCHEMBL7960787 0.74 NOTUM (0.53) NOTUMCES1TTRBCHEKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399338-A1 METHOD OF SYNTHESIZING (3S,3AR,5R,7AS,8S)- HEXAHYDRO-4H-3,5-METHANOFURO[2,3-b]PYRAN-8-OL NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-12-14 US disclosed
CN-115745825-A Method for catalyzing amide alkylation reaction by using tridentate NNO nickel complex 浙江工业大学 2023-03-07 CN disclosed
CN-114920728-A Methylidine derivative and preparation method and application thereof 中南大学 2022-08-19 CN disclosed
CN-111205202-A Quaternary carbon center-containing symmetric gem-difluoroolefin derivative and synthesis method thereof 华南理工大学 2020-05-29 CN disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9670225-B2 HIV-1 protease inhibitors and uses thereof PURDUE RESEARCH FOUNDATION (US) 2017-06-06 US disclosed
US-20170088555-A1 HIV-1 PROTEASE INHIBITORS AND USES THEREOF PURDUE RESEARCH FOUNDATION 2017-03-30 US disclosed
EP-1317013-B1 NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME MITSUBISHI CHEM CORP (JP) 2017-03-15 EP disclosed
US-20160318933-A1 FUSED PYRAZOLE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-11-03 US disclosed
WO-2013118805-A1 3-SUBSTITUTED PROLINE DERIVATIVE 大日本住友製薬株式会社 (JP) 2013-08-15 WO disclosed
US-20100120730-A1 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS NYCOMED GMBH (DE) 2010-05-13 US disclosed
US-7666865-B2 for treating pain; STROKES; ANALGESICS; do not contain substituents that are antioxidants, tropolones or coumarins NEUROMED PHARMACEUTICALS LTD. (CA) 2010-02-23 US disclosed
US-7666865-B2 for treating pain; STROKES; ANALGESICS; do not contain substituents that are antioxidants, tropolones or coumarins NEUROMED PHARMACEUTICALS LTD. (CA) 2010-02-23 US disclosed
US-20070185105-A1 Calcium channel blockers ZALICUS PHARMACEUTICALS LTD. (CA) 2007-08-09 US disclosed
US-20070185105-A1 Calcium channel blockers ZALICUS PHARMACEUTICALS LTD. (CA) 2007-08-09 US disclosed
US-6942948-B2 Nonaqueous electrolyte solution and secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2005-09-13 US disclosed
EP-1466605-A2 Calcium channel blockers Neuromed Technologies Inc. (CA) 2004-10-13 EP disclosed
US-20030165733-A1 Nonaqueous electrolyte solution and secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2003-09-04 US disclosed
EP-1317013-A1 NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2003-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185105-A1 Calcium channel blockers CACNA1S, KCNN4, CACNA1C NOTUM 2104/4885CES1 722/4885TTR 3869/4885
US-20230399338-A1 METHOD OF SYNTHESIZING (3S,3AR,5R,7AS,8S)- HEXAHYDRO-4H-3,5-METHANOFURO[2,3-b]PYRAN-8-OL HTR3C, CYP2S1, CYP4F8 NOTUM 1090/4885CES1 1020/4885TTR 2371/4885
US-20160318933-A1 FUSED PYRAZOLE DERIVATIVE DRD4, DRD2, DRD3 NOTUM 3877/4885CES1 3464/4885TTR 4799/4885
US-20100120730-A1 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS PDE5A, PDE3A, PDE2A NOTUM 803/4885CES1 398/4885TTR 4865/4885
US-20170088555-A1 HIV-1 PROTEASE INHIBITORS AND USES THEREOF PRSS1, XPNPEP1, CTRL NOTUM 2161/4885CES1 86/4885TTR 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.